BROOKLYN, N.Y., July 23, 2021 (GLOBE NEWSWIRE) — Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that on July 15, 2021, Jay Sial was granted a non-qualified stock option covering 71,000 shares of Brooklyn’s common stock (the “Time-Based Option”) and a restricted stock unit covering 35,700 shares of Brooklyn’s common stock (the “RSU”).